
天津医药 ›› 2026, Vol. 54 ›› Issue (4): 344-351.doi: 10.11958/20252647
收稿日期:2025-08-08
修回日期:2025-12-15
出版日期:2026-04-15
发布日期:2026-04-14
通讯作者:
△E-mail:作者简介:宋金萍(1983),女,副研究员,主要从事分子诊断方面研究。E-mail:基金资助:
SONG Jinping(
), CUI Yanjie, WANG Changmin△(
)
Received:2025-08-08
Revised:2025-12-15
Published:2026-04-15
Online:2026-04-14
Contact:
△E-mail:宋金萍, 崔彦杰, 王昌敏. miR-493-3p通过lncRNA CCAT2/TCF7L2轴对高糖诱导的心肌细胞损伤和凋亡的影响[J]. 天津医药, 2026, 54(4): 344-351.
SONG Jinping, CUI Yanjie, WANG Changmin. The effect of miR-493-3p on high glucose-induced myocardial cell injury and apoptosis via the lncRNA CCAT2/TCF7L2 axis[J]. Tianjin Medical Journal, 2026, 54(4): 344-351.
摘要:
目的 探讨miR-493-3p通过调节长链非编码RNA(lncRNA)结肠癌相关转录物2(CCAT2)/转录因子7样2(TCF7L2)轴对高糖(HG)诱导的心肌细胞损伤和凋亡的影响。方法 用高糖(55 mmol/L葡萄糖)培养人心肌细胞AC16,体外构建糖尿病心肌病(DCM)细胞模型。实验分组:Control组、HG组、HG+mimics-NC组、HG+miR-493-3p-mimics组、HG+干扰RNA阴性对照(Smart Silencer-NC)组、HG+干扰RNA CCAT2(Smart Silencer-CCAT2)组、HG+miR-493-3p-mimics+LV-NC组、HG+miR-493-3p-mimics+LV-CCAT2组。CCK-8法及流式细胞术检测细胞活力和凋亡率;试剂盒法检测细胞培养液中乳酸脱氢酶(LDH)和天冬氨酸转氨酶(AST)及细胞中超氧化物歧化酶(SOD)水平;双萤光素酶报告基因实验验证miR-493-3p和CCAT2之间的靶向关系;实时荧光定量PCR(qRT-PCR)检测miR-493-3p、lncRNA CCAT2、β-catenin、TCF7L2、胱天蛋白酶(Caspase)-3、细胞周期蛋白(Cyclin)D1 mRNA表达水平;Western blot检测β-catenin(核)、β-catenin(胞浆)、TCF7L2、Caspase-3、CyclinD1蛋白表达。结果 与Control组相比,HG组miR-493-3p、OD450值、SOD水平降低,lncRNA CCAT2、LDH、AST水平、细胞凋亡率、TCF7L2 mRNA和蛋白表达水平升高,上调miR-493-3p或敲低lncRNA CCAT2表达可拮抗上述变化(P<0.05)。双萤光素酶报告基因实验验证了miR-493-3p与lncRNA CCAT2和TCF7L2的靶向关系。与HG+miR-493-3p-mimics组比较,HG+miR-493-3p-mimics+LV-CCAT2组TCF7L2、β-catenin(核)及下游Caspase-3和CyclinD1 mRNA和蛋白表达均升高(P<0.05)。结论 miR-493-3p可通过抑制lncRNA CCAT2的表达减缓高糖条件下心肌细胞损伤和凋亡,二者对TCF7L2的调控存在竞争关系。
中图分类号:
| 基因名称 | 引物序列(5'→3') | 产物大小/bp |
|---|---|---|
| miR-493-3p | 上游:GTGAAGGTCTACTGTGTGC | 97 |
| 下游:GTCCAGTTTTTTTTTTTTCCTG | ||
| CCAT2 | 上游:CTTCCAGCTCCACCTCTG | 158 |
| 下游:GAGCTCAAAGGACGATGAGG | ||
| β-catenin | 上游:AAAGCGGCTGTTAGTCACTGG | 215 |
| 下游:CGAGTCATTGCATACTGTCCAT | ||
| TCF7L2 | 上游:GAAGGAGCGACAGCTTCATA | 200 |
| 下游:GGGGGAGGCGAATCTAGTAA | ||
| Caspase-3 | 上游:GAAATTGTGGAATTGATGCGTGA | 164 |
| 下游:CTACAACGATCCCCTCTGAAAAA | ||
| CyclinD1 | 上游:GGAGGAGGGTTGTGCTACAG | 289 |
| 下游:GCCTAGAACCCCACTACAGC | ||
| U6 snRNA | 上游:CTCAACTGGTGTCGTGGAGTCGGC AATTC | 102 |
| 下游:ACACTCCAGCTGGGTCACCGGGTGT AAATC | ||
| GAPDH | 上游:TGTTGCCATCAATGACCCCTT | 202 |
| 下游:CTCCACGACGTACTCAGCG |
表1 qRT-PCR引物序列
Tab.1 Primers sequence for qRT-PCR
| 基因名称 | 引物序列(5'→3') | 产物大小/bp |
|---|---|---|
| miR-493-3p | 上游:GTGAAGGTCTACTGTGTGC | 97 |
| 下游:GTCCAGTTTTTTTTTTTTCCTG | ||
| CCAT2 | 上游:CTTCCAGCTCCACCTCTG | 158 |
| 下游:GAGCTCAAAGGACGATGAGG | ||
| β-catenin | 上游:AAAGCGGCTGTTAGTCACTGG | 215 |
| 下游:CGAGTCATTGCATACTGTCCAT | ||
| TCF7L2 | 上游:GAAGGAGCGACAGCTTCATA | 200 |
| 下游:GGGGGAGGCGAATCTAGTAA | ||
| Caspase-3 | 上游:GAAATTGTGGAATTGATGCGTGA | 164 |
| 下游:CTACAACGATCCCCTCTGAAAAA | ||
| CyclinD1 | 上游:GGAGGAGGGTTGTGCTACAG | 289 |
| 下游:GCCTAGAACCCCACTACAGC | ||
| U6 snRNA | 上游:CTCAACTGGTGTCGTGGAGTCGGC AATTC | 102 |
| 下游:ACACTCCAGCTGGGTCACCGGGTGT AAATC | ||
| GAPDH | 上游:TGTTGCCATCAATGACCCCTT | 202 |
| 下游:CTCCACGACGTACTCAGCG |
| 组别 | miR-493-3p | lncRNA CCAT2 |
|---|---|---|
| Control组 | 1.01±0.15 | 1.01±0.12 |
| HG组 | 0.30±0.02a | 2.24±0.38a |
| HG+mimics-NC组 | 0.31±0.03 | 2.07±0.21 |
| HG+miR-493-3p-mimics组 | 0.92±0.08bc | 1.37±0.05bc |
| HG+Smart Silencer-NC组 | 0.36±0.07 | 2.08±0.23 |
| HG+Smart Silencer-CCAT2组 | 1.14±0.16bd | 0.94±0.21bd |
| F | 130.960** | 58.594** |
表2 各组AC16细胞miR-493-3p和lncRNA CCAT2表达水平比较 (n=3,$\bar{x}±s$)
Tab.2 Comparison of miR-493-3p and lncRNA CCAT2 expression between six groups of AC16 cells
| 组别 | miR-493-3p | lncRNA CCAT2 |
|---|---|---|
| Control组 | 1.01±0.15 | 1.01±0.12 |
| HG组 | 0.30±0.02a | 2.24±0.38a |
| HG+mimics-NC组 | 0.31±0.03 | 2.07±0.21 |
| HG+miR-493-3p-mimics组 | 0.92±0.08bc | 1.37±0.05bc |
| HG+Smart Silencer-NC组 | 0.36±0.07 | 2.08±0.23 |
| HG+Smart Silencer-CCAT2组 | 1.14±0.16bd | 0.94±0.21bd |
| F | 130.960** | 58.594** |
| 组别 | OD450值 | LDH/(U/L) | ||||
|---|---|---|---|---|---|---|
| Control组 | 0.89±0.03 | 89.47±17.99 | ||||
| HG组 | 0.63±0.03a | 396.68±43.54a | ||||
| HG+mimics-NC组 | 0.66±0.04 | 374.51±78.11 | ||||
| HG+miR-493-3p-mimics组 | 0.76±0.04bc | 176.56±35.66bc | ||||
| HG+Smart Silencer-NC组 | 0.62±0.04 | 330.88±36.32 | ||||
| HG+Smart Silencer-CCAT2组 | 0.75±0.05bd | 234.03±18.54bd | ||||
| F | 585.245** | 20.861** | ||||
| 组别 | AST/ (U/L) | SOD/ (U/mgprot) | 凋亡率/ % | |||
| Control组 | 13.90±3.48 | 16.58±1.98 | 2.09±0.46 | |||
| HG组 | 76.49±18.98a | 3.73±0.82a | 13.62±1.12a | |||
| HG+mimics-NC组 | 71.89±11.50 | 3.98±0.82 | 13.26±1.12 | |||
| HG+miR-493-3p-mimics组 | 26.79±6.50bc | 9.63±0.56bc | 7.24±0.56bc | |||
| HG+Smart Silencer-NC组 | 69.03±12.08 | 4.09±0.96 | 12.77±1.10 | |||
| HG+Smart Silencer-CCAT2组 | 36.69±4.91bd | 11.39±1.93bd | 8.04±0.51bd | |||
| F | 7.050* | 52.465** | 78.865** | |||
表3 各组AC16细胞OD450值、心肌损伤标志物和细胞凋亡率比较 (n=3,$\bar{x}±s$)
Tab.3 Comparison of OD450 value, myocardial cell injury markers and apoptosis rate between six groups of AC16 cells
| 组别 | OD450值 | LDH/(U/L) | ||||
|---|---|---|---|---|---|---|
| Control组 | 0.89±0.03 | 89.47±17.99 | ||||
| HG组 | 0.63±0.03a | 396.68±43.54a | ||||
| HG+mimics-NC组 | 0.66±0.04 | 374.51±78.11 | ||||
| HG+miR-493-3p-mimics组 | 0.76±0.04bc | 176.56±35.66bc | ||||
| HG+Smart Silencer-NC组 | 0.62±0.04 | 330.88±36.32 | ||||
| HG+Smart Silencer-CCAT2组 | 0.75±0.05bd | 234.03±18.54bd | ||||
| F | 585.245** | 20.861** | ||||
| 组别 | AST/ (U/L) | SOD/ (U/mgprot) | 凋亡率/ % | |||
| Control组 | 13.90±3.48 | 16.58±1.98 | 2.09±0.46 | |||
| HG组 | 76.49±18.98a | 3.73±0.82a | 13.62±1.12a | |||
| HG+mimics-NC组 | 71.89±11.50 | 3.98±0.82 | 13.26±1.12 | |||
| HG+miR-493-3p-mimics组 | 26.79±6.50bc | 9.63±0.56bc | 7.24±0.56bc | |||
| HG+Smart Silencer-NC组 | 69.03±12.08 | 4.09±0.96 | 12.77±1.10 | |||
| HG+Smart Silencer-CCAT2组 | 36.69±4.91bd | 11.39±1.93bd | 8.04±0.51bd | |||
| F | 7.050* | 52.465** | 78.865** | |||
| 组别 | mRNA | 蛋白 |
|---|---|---|
| Control组 | 1.01±0.08 | 1.00±0.05 |
| HG组 | 1.85±0.04a | 1.64±0.10a |
| HG+mimics-NC组 | 1.80±0.07 | 1.53±0.11 |
| HG+miR-493-3p-mimics组 | 1.21±0.09bc | 1.18±0.09bc |
| HG+Smart Silencer-NC组 | 2.18±0.36 | 1.81±0.19 |
| HG+Smart Silencer-CCAT2组 | 1.47±0.18bd | 1.29±0.16bd |
| F | 3.923* | 4.011* |
表4 各组TCF7L2 mRNA和蛋白表达量比较 (n=3,$\bar{x}±s$)
Tab.4 Comparison of TCF7L2 mRNA and protein expression between six groups of AC16 cells
| 组别 | mRNA | 蛋白 |
|---|---|---|
| Control组 | 1.01±0.08 | 1.00±0.05 |
| HG组 | 1.85±0.04a | 1.64±0.10a |
| HG+mimics-NC组 | 1.80±0.07 | 1.53±0.11 |
| HG+miR-493-3p-mimics组 | 1.21±0.09bc | 1.18±0.09bc |
| HG+Smart Silencer-NC组 | 2.18±0.36 | 1.81±0.19 |
| HG+Smart Silencer-CCAT2组 | 1.47±0.18bd | 1.29±0.16bd |
| F | 3.923* | 4.011* |
图3 Western blot检测各组AC16细胞中TCF7L2蛋白表达情况 A—F分别为Control组、HG组、HG+mimics-NC组、HG+miR-493-3p-mimics组、HG+Smart Silencer-NC组及HG+Smart Silencer-CCAT2组。
Fig.3 The expression of TCF7L2 protein in AC16 cells of each group detected by Western blot assay
| 组别 | miR-493-3p | CCAT2 | |||
|---|---|---|---|---|---|
| Control组 | 1.01±0.15 | 1.01±0.13 | |||
| HG组 | 0.33±0.04a | 2.04±0.30a | |||
| HG+mimics-NC组 | 0.30±0.06 | 2.10±0.12 | |||
| HG+miR-493-3p-mimics组 | 0.92±0.08bc | 1.37±0.05bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 0.89±0.07 | 1.44±0.18 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 0.44±0.07d | 1.92±0.27d | |||
| F | 48.739** | 13.234** | |||
| 组别 | OD450值 | 凋亡率/% | |||
| Control组 | 0.88±0.04 | 2.14±0.52 | |||
| HG组 | 0.64±0.03a | 13.28±1.07a | |||
| HG+mimics-NC组 | 0.65±0.03 | 13.44±1.21 | |||
| HG+miR-493-3p-mimics组 | 0.76±0.04bc | 7.24±0.56bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 0.75±0.03 | 7.42±0.51 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 0.66±0.04d | 10.02±0.91bd | |||
| F | 36.704** | 78.865** |
表5 各组miR-493-3p 和CCAT2基因表达和增殖及凋亡率比较 (n=3,$\bar{x}±s$)
Tab.5 Comparison of miR-493-3p and CCAT2 expression, cell proliferation and apoptosis rate between six groups of AC16 cells
| 组别 | miR-493-3p | CCAT2 | |||
|---|---|---|---|---|---|
| Control组 | 1.01±0.15 | 1.01±0.13 | |||
| HG组 | 0.33±0.04a | 2.04±0.30a | |||
| HG+mimics-NC组 | 0.30±0.06 | 2.10±0.12 | |||
| HG+miR-493-3p-mimics组 | 0.92±0.08bc | 1.37±0.05bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 0.89±0.07 | 1.44±0.18 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 0.44±0.07d | 1.92±0.27d | |||
| F | 48.739** | 13.234** | |||
| 组别 | OD450值 | 凋亡率/% | |||
| Control组 | 0.88±0.04 | 2.14±0.52 | |||
| HG组 | 0.64±0.03a | 13.28±1.07a | |||
| HG+mimics-NC组 | 0.65±0.03 | 13.44±1.21 | |||
| HG+miR-493-3p-mimics组 | 0.76±0.04bc | 7.24±0.56bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 0.75±0.03 | 7.42±0.51 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 0.66±0.04d | 10.02±0.91bd | |||
| F | 36.704** | 78.865** |
| 组别 | LDH/ (U/L) | AST/ (U/L) | SOD/ (U/mgprot) |
|---|---|---|---|
| Control组 | 83.15±18.17 | 15.74±1.95 | 14.21±2.47 |
| HG组 | 415.67±40.31a | 74.00±16.87a | 3.73±0.74a |
| HG+mimics-NC组 | 403.80±63.98 | 76.49±11.71 | 3.90±0.32 |
| HG+miR-493-3p-mimics组 | 176.56±35.66bc | 26.79±6.50bc | 9.63±0.56bc |
| HG+miR-493-3p-mimics+ LV-NC组 | 168.65±30.12 | 29.55±8.94 | 9.27±1.36 |
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 342.83±55.47d | 60.38±12.15d | 4.27±0.31d |
| F | 20.681** | 7.050** | 52.465** |
表6 各组AC16细胞心肌损伤标志物比较 (n=3,$\bar{x}±s$)
Tab.6 Comparison of myocardial cell injury markers between six groups of AC16 cells
| 组别 | LDH/ (U/L) | AST/ (U/L) | SOD/ (U/mgprot) |
|---|---|---|---|
| Control组 | 83.15±18.17 | 15.74±1.95 | 14.21±2.47 |
| HG组 | 415.67±40.31a | 74.00±16.87a | 3.73±0.74a |
| HG+mimics-NC组 | 403.80±63.98 | 76.49±11.71 | 3.90±0.32 |
| HG+miR-493-3p-mimics组 | 176.56±35.66bc | 26.79±6.50bc | 9.63±0.56bc |
| HG+miR-493-3p-mimics+ LV-NC组 | 168.65±30.12 | 29.55±8.94 | 9.27±1.36 |
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 342.83±55.47d | 60.38±12.15d | 4.27±0.31d |
| F | 20.681** | 7.050** | 52.465** |
| 组别 | TCF7L2 | β-catenin | |||
|---|---|---|---|---|---|
| Control组 | 0.99±0.09 | 1.09±0.06 | |||
| HG组 | 1.87±0.01a | 1.85±0.05a | |||
| HG+mimics-NC组 | 1.82±0.04 | 1.77±0.02 | |||
| HG+miR-493-3p-mimics组 | 1.21±0.09bc | 1.08±0.09bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 1.25±0.01 | 1.10±0.05 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 1.73±0.11d | 1.68±0.08d | |||
| F | 56.535** | 54.914** | |||
| 组别 | Caspase-3 | CyclinD1 | |||
| Control组 | 1.05±0.12 | 1.02±0.08 | |||
| HG组 | 2.20±0.08a | 1.81±0.14a | |||
| HG+mimics-NC组 | 2.27±0.09 | 1.86±0.18 | |||
| HG+miR-493-3p-mimics组 | 1.25±0.09bc | 1.22±0.22bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 1.24±0.13 | 1.25±0.10 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 1.93±0.11d | 1.64±0.10d | |||
| F | 64.306** | 16.067** |
表7 各组Wnt信号通路基因表达情况比较 (n=3,$\bar{x}±s$)
Tab.7 Comparison of gene expression of Wnt pathway between six groups of AC16 cells
| 组别 | TCF7L2 | β-catenin | |||
|---|---|---|---|---|---|
| Control组 | 0.99±0.09 | 1.09±0.06 | |||
| HG组 | 1.87±0.01a | 1.85±0.05a | |||
| HG+mimics-NC组 | 1.82±0.04 | 1.77±0.02 | |||
| HG+miR-493-3p-mimics组 | 1.21±0.09bc | 1.08±0.09bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 1.25±0.01 | 1.10±0.05 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 1.73±0.11d | 1.68±0.08d | |||
| F | 56.535** | 54.914** | |||
| 组别 | Caspase-3 | CyclinD1 | |||
| Control组 | 1.05±0.12 | 1.02±0.08 | |||
| HG组 | 2.20±0.08a | 1.81±0.14a | |||
| HG+mimics-NC组 | 2.27±0.09 | 1.86±0.18 | |||
| HG+miR-493-3p-mimics组 | 1.25±0.09bc | 1.22±0.22bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 1.24±0.13 | 1.25±0.10 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 1.93±0.11d | 1.64±0.10d | |||
| F | 64.306** | 16.067** |
| 组别 | TCF7L2 | β-catenin(核) | ||||
|---|---|---|---|---|---|---|
| Control组 | 0.39±0.02 | 0.38±0.03 | ||||
| HG组 | 0.61±0.04a | 0.87±0.06a | ||||
| HG+mimics-NC组 | 0.60±0.05 | 0.88±0.06 | ||||
| HG+miR-493-3p-mimics组 | 0.44±0.03bc | 0.55±0.11bc | ||||
| HG+miR-493-3p-mimics+ LV-NC组 | 0.47±0.02 | 0.55±0.06 | ||||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 0.56±0.03d | 0.82±0.05d | ||||
| F | 24.892** | 55.854** | ||||
| 组别 | β-catenin(胞浆) | Caspase-3 | CyclinD1 | |||
| Control组 | 0.52±0.03 | 0.24±0.03 | 0.29±0.01 | |||
| HG组 | 0.35±0.03a | 0.66±0.03a | 0.63±0.08a | |||
| HG+mimics-NC组 | 0.34±0.02 | 0.63±0.02 | 0.61±0.09 | |||
| HG+miR-493-3p-mimics组 | 0.47±0.04bc | 0.44±0.01bc | 0.43±0.02bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 0.47±0.02 | 0.47±0.03 | 0.42±0.06 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 0.32±0.02d | 0.61±0.02d | 0.58±0.07d | |||
| F | 37.876** | 131.691** | 11.536** | |||
表8 各组Wnt信号通路蛋白表达的比较 (n=3,$\bar{x}±s$)
Tab.8 Comparison of protein expression of Wnt pathway between six groups of AC16 cells
| 组别 | TCF7L2 | β-catenin(核) | ||||
|---|---|---|---|---|---|---|
| Control组 | 0.39±0.02 | 0.38±0.03 | ||||
| HG组 | 0.61±0.04a | 0.87±0.06a | ||||
| HG+mimics-NC组 | 0.60±0.05 | 0.88±0.06 | ||||
| HG+miR-493-3p-mimics组 | 0.44±0.03bc | 0.55±0.11bc | ||||
| HG+miR-493-3p-mimics+ LV-NC组 | 0.47±0.02 | 0.55±0.06 | ||||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 0.56±0.03d | 0.82±0.05d | ||||
| F | 24.892** | 55.854** | ||||
| 组别 | β-catenin(胞浆) | Caspase-3 | CyclinD1 | |||
| Control组 | 0.52±0.03 | 0.24±0.03 | 0.29±0.01 | |||
| HG组 | 0.35±0.03a | 0.66±0.03a | 0.63±0.08a | |||
| HG+mimics-NC组 | 0.34±0.02 | 0.63±0.02 | 0.61±0.09 | |||
| HG+miR-493-3p-mimics组 | 0.47±0.04bc | 0.44±0.01bc | 0.43±0.02bc | |||
| HG+miR-493-3p-mimics+ LV-NC组 | 0.47±0.02 | 0.47±0.03 | 0.42±0.06 | |||
| HG+miR-493-3p-mimics+ LV-CCAT2组 | 0.32±0.02d | 0.61±0.02d | 0.58±0.07d | |||
| F | 37.876** | 131.691** | 11.536** | |||
图5 Western blot检测各组AC16细胞中Wnt通路蛋白表达 A—F分别为Control组、HG组、HG+mimics-NC组、HG+miR-493-3p-mimics组、HG+miR-493-3p-mimics+LV-NC组及HG+miR-493-3p-mimics+LV-CCAT2组。
Fig.5 Western blot assay of protein expression of Wnt pathway in each group of AC16 cells
| [1] | LIU Y, YUAN J, ZHANG Y, et al. Non-coding RNA as a key regulator and novel target of apoptosis in diabetic cardiomyopathy:Current status and future prospects[J]. Cell Signal, 2025, 128:111632. doi:10.1016/j.cellsig.2025.111632. |
| [2] | MAO H, HU J, YU C, et al. MicroRNAs in anthracycline cardiotoxicity:biomarkers,mechanisms,and therapeutic advances[J]. Front Cardiovasc Med, 2025, 12:1614878. doi:10.3389/fcvm.2025.1614878. |
| [3] | ŻAREK-STARZEWSKA A, KLIMCZAK-TOMANIAK D, MĄDRECKA A, et al. From type 2 diabetes mellitus to diabetic cardiomyopathy - a systematic review on the role of microRNA[J]. Curr Diab Rep, 2025, 25(1):42. doi:10.1007/s11892-025-01590-6. |
| [4] | ZHUO X, BAI K, WANG Y, et al. Long-chain noncoding RNA-GAS5/hsa-miR-138-5p attenuates high glucose-induced cardiomyocyte damage by targeting CYP11B2[J]. Biosci Rep, 2021, 41(9):BSR20202232. doi:10.1042/BSR20202232. |
| [5] | 吕朝阳, 黄婷, 徐在革, 等. LncRNA TUG1通过调节miR-181b-5p/PDCD4轴对高糖诱导的心肌细胞凋亡的影响[J]. 天津医药, 2023, 51(12):1281-1287. |
| LYU C Y, HUANG T, XU Z G, et al. Impact of LncRNA TUG1 on high glucose-induced cardiomyocyte apoptosis by regulating the miR-181b-5p/PDCD4 axis[J]. Tianjin Med J, 2023, 51(12):1281-1287. doi:10.11958/20230523. | |
| [6] | LIU Q, YANG H, HUA H. Overexpression of miR-493-3p suppresses ovarian cancer cell proliferation,migration and invasion through downregulating DPY30[J]. Reprod Biol, 2022, 22(2):100610. doi:10.1016/j.repbio.2022.100610. |
| [7] | DING D, YANG F, CHEN Z, et al. Circ_0007385 regulates cell proliferation,apoptosis and stemness via targeting miR-493-3p/RAB22A axis in non-small cell lung cancer[J]. Thorac Cancer, 2022, 13(4):571-581. doi:10.1111/1759-7714.14300. |
| [8] | YAO M, MAO X, ZHANG Z, et al. Tumor-derived CircRNA_102191 promotes gastric cancer and facilitates M2 macrophage polarization[J]. Cell Cycle, 2023, 22(18):2003-2017. doi:10.1080/15384101.2023.2271341. |
| [9] | SU Y, ZHAO L, LEI D, et al. Inhibition of circ_0073932 attenuates myocardial ischemia-reperfusion injury via miR-493-3p/FAF1/JNK[J]. In Vitro Cell Dev Biol Anim, 2024, 60(6):628-643. doi:10.1007/s11626-024-00900-8. |
| [10] | JIA L, WANG W Z, LIU H, et al. LncRNA TTN-AS1 exacerbates extracellular matrix accumulation via miR-493-3p/FOXP2 axis in diabetic nephropathy[J]. J Genet, 2023, 102:11. doi:10.1007/s12041-022-01397-4. |
| [11] | 张海川. 孕期高脂饮食上调子代心肌miR-493-3p导致心肌肥厚[D]. 广州: 广州医科大学, 2020. |
| ZHANG H C. Maternal high-fat diet upregulates miR-493-3p in offspring cardiac muscle leading to cardiac hypertrophy[D]. Guangzhou: Guangzhou Medical University, 2020. | |
| [12] | 宋金萍, 崔彦杰, 刘熔. 高糖培养条件下lncRNACCAT2调控心肌细胞损伤和凋亡的机制研究[J]. 国际检验医学杂志, 2024, 45(5):578-584. |
| SONG J P, CUI Y J, LIU R. Mechanism of lncRNA CCAT2 regulating cardiomyocyte injury and apoptosis under high glucose culture condition[J]. Int J Lab Med, 2024, 45(5):578-584. doi:10.3969/j.issn.1673-4130.2024.05.014. | |
| [13] | WANG X, ZHENG L, LU F. Association between estimated glucose disposal rate and heart failure in patients with diabetes or prediabetes:a cross-sectional study[J]. BMC Public Health, 2025, 25(1):2711. doi:10.1186/s12889-025-24154-5. |
| [14] | GROBMAN B, MANSUR A, LU C Y. Disparities in heart failure deaths among people with diabetes in the United States:1999-2020[J]. Diabetes Obes Metab, 2025, 27(6):2977-2984. doi:10.1111/dom.16301. |
| [15] | 解有成, 王菲, 徐进, 等. SIRT1在糖尿病心肌病发病中的研究进展[J]. 天津医药, 2024, 52(4):443-448. |
| XIE Y C, WANG F, XU J, et al. Research progress of SIRT1 in the pathogenesis of diabetic cardiomyopathy[J]. Tianjin Med J, 2024, 52(4):443-448. doi:10.11958/20231289. | |
| [16] | PIRLOG R, DRULA R, NUTU A, et al. The roles of the colon cancer associated transcript 2(CCAT2)long non-coding RNA in cancer:A comprehensive characterization of the tumorigenic and molecular functions[J]. Int J Mol Sci, 2021, 22(22):12491. doi:10.3390/ijms222212491. |
| [17] | GHOLIZADEH N, YOUSEFIAN M, MOHAMMADPOUR H, et al. Long non-coding RNAs PVT1,CCAT2,and TCF7L2,and miR-33 and c-Myc expression in oral squamous cell carcinoma and oral lichen planus patients[J]. J Craniomaxillofac Surg, 2025, 53(8):1197-1204. doi:10.1016/j.jcms.2025.04.006. |
| [18] | ZHAN K, SONG X, ZHANG Q, et al. Propofol-induced miR-493-3p inhibits growth and invasion of gastric cancer through suppression of DKK1-mediated Wnt/β-catenin signaling activation[J]. Dis Markers, 2023, 2023:7698706. doi:10.1155/2023/7698706. |
| [1] | 刘瑢, 项艳曾, 马丽娟, 张鹏. 腺病毒介导的SPRY1过表达对肝细胞癌凋亡和自噬的影响[J]. 天津医药, 2026, 54(4): 337-343. |
| [2] | 翟志红, 李润琦, 杜晴晴, 秦文娟. 葡萄籽原花青素提取物对多柔比星致慢性心脏毒性的防治作用[J]. 天津医药, 2026, 54(4): 358-363. |
| [3] | 杨晓芳, 贾新燕, 丰文君. miR-181a-5p通过HMGB1/NF-κB信号通路调控狼疮性肾炎小鼠肾小球系膜细胞增殖和凋亡[J]. 天津医药, 2026, 54(3): 232-237. |
| [4] | 张婧, 魏玉英, 宁海虹, 韦红梅, 王嘉玮, 曹薇, 吴宾. DUSP9在2型糖尿病心肌病小鼠心肌损伤中的保护作用及其机制[J]. 天津医药, 2026, 54(3): 238-244. |
| [5] | 王喆, 邱林, 马贲. 番茄来源胞外囊泡样颗粒对口腔鳞状细胞癌的作用效果研究[J]. 天津医药, 2026, 54(2): 145-150. |
| [6] | 李志伟, 张会超, 杨凤鸣, 曾垂义. 基于miR-144-3p/MAPK1通路探讨红参总皂苷对扩张型心肌病小鼠心肌细胞凋亡的影响[J]. 天津医药, 2026, 54(1): 23-29. |
| [7] | 李霖, 李丹阳, 崔岩. 糖尿病肾病合并心脏自主神经病变随机森林模型的构建及验证[J]. 天津医药, 2026, 54(1): 41-45. |
| [8] | 赵兰君, 李良惠, 马馨, 巩娇娇, 郑臣辉, 石琳. 穿心莲内酯调控STAT3/GPX4通路对骨髓瘤细胞增殖和凋亡的影响[J]. 天津医药, 2026, 54(1): 8-13. |
| [9] | 孔翠文, 路延双, 孙丽萍, 于芬芬. LncRNA SNHG14靶向miR-30a-5p对高糖诱导的足细胞损伤的影响[J]. 天津医药, 2025, 53(9): 903-909. |
| [10] | 牛书林, 王宙明, 刘茗宇, 关欣, 李梦琦, 田轶魁, 杨振文, 杜鑫. 经导管二尖瓣“瓣中瓣”置换术治疗人工二尖瓣生物瓣衰败的安全性和有效性分析[J]. 天津医药, 2025, 53(9): 993-999. |
| [11] | 万艳波, 刘明, 王勇. 秦皮甲素调节HMGB1/RAGE信号通路对缺氧/复氧诱导的心肌细胞损伤的影响[J]. 天津医药, 2025, 53(8): 796-801. |
| [12] | 刘海威, 杨洁, 王力, 蒙诗波, 唐旭松, 刘成仁, 王永旺. 木犀草素通过NFE2L2/x-CT/GPX4信号轴调控ROS水平抑制胶质母细胞瘤[J]. 天津医药, 2025, 53(7): 673-678. |
| [13] | 陈英, 郭长英, 张静, 李娟, 陈丰毅. 基于术前肺动脉压评估心脏移植术后右心衰竭的发生风险[J]. 天津医药, 2025, 53(7): 751-755. |
| [14] | 韩建存, 周谊. 川陈皮素调节FAK/AKT信号通路对喉鳞状细胞癌细胞增殖和凋亡的影响[J]. 天津医药, 2025, 53(6): 561-565. |
| [15] | 陈珍进, 金晓青, 祁安宁, 韩崇旭. 血浆血管性血友病因子抗原水平对老年急性心肌梗死患者长期预后的预测价值[J]. 天津医药, 2025, 53(6): 589-593. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||